

REMARKS

This Amendment and accompanying Request for Continued Examination are submitted after submission of Applicants' Notice of Appeal. Applicants respectfully request that prosecution of this application be reopened in accordance with MPEP § 706.07(h)(X).

Claims 1-12, 19-22 and new claims 26-29 are pending in this case. Claims 13-18 and 23-25 were previously canceled without prejudice or disclaimer. The February 14, 2005 Advisory Action (after the filing of the Notice of Appeal) maintained the §112 rejection of claims 1-12 and 19-22 as the term "a typical amount of medicament...to achieve a bioequivalent effect..." was alleged to be not supported by the specification. The claims have been amended to more clearly articulate the subject matter therein. The present amendment has neither added new matter to nor narrowed the scope of the claims.

Support for the present claims may be found at:

page 1 lines 19-23;

page 2 lines 7-25;

page 3 lines 3-22;

page 4 line 32 through page 5 line 16;


page 6 lines 8-19;

page 7 lines 27-32; and

page 13 lines 16-28.

In view of the foregoing, Applicants respectfully request that the §112 rejections be withdrawn and that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

Robert M. Barrett
Reg. No. 30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

Dated: May 11, 2004